| Literature DB >> 31364827 |
Weitie Wang1, Tiance Wang1, Hulin Piao1, Bo Li1, Yong Wang1, Dan Li1, Zhicheng Zhu1, Rihao Xu1, Kexiang Liu1.
Abstract
OBJECTIVE: To evaluate the changes of the mitral valve geometrics and the degrees of moderate mitral regurgitation (MR) in patients undergoing aortic valve replacement (AVR) for aortic stenosis (AS).Entities:
Keywords: Aortic Valve Stenosis; Atrial Fibrillation; Echocardiography; Mitral Valve Insufficiency; Retrospective Studies; Stroke Volume; Ventricular Remodeling
Mesh:
Year: 2019 PMID: 31364827 PMCID: PMC6894038 DOI: 10.21470/1678-9741-2018-0331
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Baseline and procedural characteristics.
| AS with moderate MR (n=49) | |
|---|---|
| Age (years) | 52.6±12.2 |
| Age > 60 years | 9(18.4%) |
| Males | 22(44.9%) |
| Obesity (BMI > 30 kg/m2) | 2(4.5%) |
| Smoking | 21(42.9%) |
| NYHA class III-IV | 35(71.4%) |
| Hypertension | 19(38.8%) |
| Diabetes mellitus | 11(22.5%) |
| Chronic renal dysfunction | 0 |
| Congestive heart failure | 4(8.2%) |
| Atrial fibrillation | 0 |
| Hyperlipemia | 5(10.2%) |
| COPD | 5(10.2%) |
| Prior cerebrovascular accident | 2(4.5%) |
| LVEF | 56.8±12.9% |
| LVEF < 50% | 8(16.3) |
| Bicuspid aortic valve stenosis | 18(36.7%) |
| Rheumatic disease | 13(26.5%) |
| Calcific disease | 18(36.7%) |
AS=aortic stenosis; BMI=body mass index; COPD=chronic obstructive pulmonary disease; LVEF=left ventricular ejection fraction; MR=mitral regurgitation; NYHA=New York Heart Association
Intraoperative data.
| AS with moderate MR (n=49) | |
|---|---|
| Operation time (min) | 208.2±31.2 |
| Cardiopulmonary bypass time (min) | 32.5±7.3 |
| Cross-clamp time (min) | 24.3±3.4 |
| Mechanical valves | 37 |
| Tissue valves | 12 |
AS=aortic stenosis; MR=mitral regurgitation
Postoperative data.
| AS with moderate MR (n=49) | |
|---|---|
| Surgical mortality | 0 |
| Resternotomy for bleeding | 0 |
| Duration of mechanic ventilation (hour) | 7.5±2.2 |
| Intensive care unit stay (days) | 2.0±0.2 |
| Hospital stay (days) | 10.4±0.2 |
| Ventricular arrhythmia | 0 |
| Atrial arrhythmia | 6(12.2%) |
| Respiratory failure | 0 |
| Pneumonia | 0 |
| Neurologic complications | 0 |
| Low output syndrome | 0 |
| Drainage during the first 12 hours (ml) | 259.2±67.1 |
| Tamponade | 0 |
| Stroke | 0 |
| Deep sternal wound infection | 0 |
AS=aortic stenosis; MR=mitral regurgitation
Intraoperative transesophageal echocardiographic data.
| Variable (n=49) | Pre-CPB (n=49) | Separation from CPB (n=49) | |
|---|---|---|---|
| Annular area (cm2) | 5.4±0.5 | 4.4±0.2 | <0.001 |
| AL-PM diameter (cm) | 3.7±0.2 | 3.2±0.2 | <0.001 |
| AP diameter (cm) | 1.8±0.1 | 1.7±0.1 | <0.001 |
| LVEDV (ml) | 125.6±16.4 | 124.7±15.9 | 0.7833 |
| LV size (mm) | 39.8±2.3 | 39.7±2.4 | 0.8337 |
| LA size (mm) | 32.4±2.3 | 31.9±2.2 | 0.2742 |
AL-PM=anterolateral-posteromedial; AP=anterior-posterior; CPB=cardiopulmonary bypass; LA=left atrial; LV=left ventricular; LVEDV=left ventricular end-diastolic volume
Fig. 1Changes in grade of mitral regurgitation after aortic valve replacement.
Transthoracic echocardiographic data.
| Variable | Before operation | 10 days after operation | Midterm follow-up after operation | |
|---|---|---|---|---|
| Patients | N=49 | N=49 | N=49 | |
| LA size | 37.4±2.2 | 30.7±2.0[ | 27.4±1.5[ | 344.1 |
| LV size | 53.8±2.1 | 41.2±3.8[ | 41.0±3.4[ | 259.9 |
| EDV | 146.8±15.3 | 95.3±6.2[ | 94.1±7.1[ | 412.0 |
| EF | 53.7±8.4 | 51.7±6.3[ | 57.0±7.0[ | 6.612 |
| MR | 2.9±0.2 | 0.6±0.04[ | 0.4±0.1[ | 5498 |
| Mean NYHA class | 3.3±0.3 | 2.0±0.1[ | 1.5±0.1[ | 1154 |
| Left ventricular to aortic pressure gradient | 117.4±26.2 | 32.1±14.4[ | 27.2±8.1[ | 394.2 |
P<0.05
= compare with before operation data;
= compare with 10 days after operation data EDV=end-diastolic volume; EF=ejection fraction; LA=left atrial; LV=left ventricular; MR=mitral regurgitation; NYHA=New York Heart Association
Fig. 2Changes in 3D mitral valve model after aortic valve replacement (AVR). Screen capture demonstrates a completed 3D mitral valve model. The 2D long-axis echocardiographic views represent orthogonal planes with a cross-sectional coronal plane for annular area tracing. The 3D model shows the final model with automatically labeled landmarks and diameters. A, B=Pre-AVR analysis. C, D=Post-AVR analysis in the same patient demonstrating a reduction in the mitral annular area (from 5.91 to 4.25 cm2), anterior-posterior diameter (from 1.92 to 1.68 cm), and anterolateral-posteromedial diameter (from 3.80 to 3.27 cm).
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AF | = Atrial fibrillation | IABP | = Intra-aortic balloon pump | |
| AL-PM | = Anterolateral-posteromedial | ICU | = Intensive care unit | |
| AP | = Anterior-posterior | LA | = Left atrial | |
| AS | = Aortic stenosis | LCOS | = Low cardiac output syndrome | |
| AVR | = Aortic valve replacement | LV | = Left ventricular | |
| BMI | = Body mass index | LVEDV | = Left ventricular end-diastolic volume | |
| COPD | = Chronic obstructive pulmonary disease | LVEF | = Left ventricular ejection fraction | |
| CPB | = Cardiopulmonary bypass | MR | = Mitral regurgitation | |
| CRD | = Chronic renal dysfunction | NYHA | = New York Heart Association | |
| CVP | = Central venous pressure | SD | = Standard deviation | |
| DM | = Diabetes mellitus | SPSS | = Statistical Package for the Social Sciences | |
| EDV | = End-diastolic volume | TEE | = Transesophageal echocardiography | |
| EF | = Ejection fraction | TTE | = Transthoracic echocardiography | |
| Authors’ roles & responsibilities | |
|---|---|
| WW | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| TW | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| HP | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| BL | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| YW | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| DL | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| ZZ | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| RX | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |
| KL | Conceived the study, and participated in its design and coordination and helped to draft the manuscript; final approval of the version to be published |